NeuroScientific Biopharmaceuticals Limited announced the appointment of Mr. Paul Rennie as Interim CEO, effective immediately. Mr. Rennie will remain as Chairman of the Company, whilst taking a more active role in the executive management as the company conducts a global search for a permanent CEO with appropriate regulatory, technical and commercial experience. As part of his appointment as interim CEO and subject to shareholder approval (if required), Mr. Rennie will be granted 2 million performance rights, vesting upon the company achieving an approved ethics submission in relation to a Phase I clinical trial for EmtinB and expiring three years from grant.

Mr. Rennie's remuneration remains unchanged. In addition to his role at NSB, Mr. Rennie is Chairman of, and is currently transitioning to the role of Managing Director with ASX-listed Paradigm Biopharmaceuticals Ltd. ("Paradigm"). Mr. Rennie will serve his role as NeuroScientific Interim CEO concurrently to his roles within Paradigm.